
USPH Stock Forecast & Price Target
USPH Analyst Ratings
Bulls say
US Physical Therapy is expected to continue generating strong revenue, with increased profitability from a growing industrial injury prevention segment and potential M&A opportunities in both PT and IIP. However, risks include potential wage pressure, Medicare reimbursement pressure, and economic contraction affecting demand for PT services. Estimates for 2026 and 2027 project revenue of $836.4M and $878.0M, respectively, with EBITDA of $104M in 2026 and $120M in 2027. The recent acquisition of an eight-clinic PT practice and a 70% interest in an IIP business, as well as continued de novo clinic openings, show strategic growth potential for the company.
Bears say
US Physical Therapy is currently facing headwinds from adverse weather conditions, which have affected its revenue in the first quarter of 2026. Its recent financial results showed improvement in same-store visits and revenue from its Industrial Injury Prevention segment. While the company has promising partnerships with hospitals, its valuation has been compressed in the past few years and may not justify a high target price at this time. Overall, there are concerns about the company's ability to sustain growth and generate strong profits in the near future, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of U.S. Physical Therapy and is not a guaranteed prediction by Public.com or investment advice.
USPH Analyst Forecast & Price Prediction
Start investing in USPH
Order type
Buy in
Order amount
Est. shares
0 shares